Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1563-1570

  Corless, Christopher L ^a   Ballman, Karla V ^b   Antonescu, Cristina R ^c   Kolesnikova, Violetta ^a   Maki, Robert G ^d   Pisters, Peter W T ^e   Blackstein, Martin E ^f   Blanke, Charles D ^a   Demetri, George D ^g   Heinrich, Michael C ^a   Von Mehren, Margaret ^h   Patel, Shreyaskumar ^e   McCarter, Martin D ⁱ   Owzar, Kouros ^j   DeMatteo, Ronald P ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITOSIS RATE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR LOCALIZATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGED; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MITOSIS INDEX; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PHENOTYPE; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84903816384     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2046     Document Type: Article

References (35)

1. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
2. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006 (Pubitemid 44275331)
3. Heinrich MC, Owzar K, Corless CL, et al: Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360-5367, 2008
4. Gastrointestinal Stromal Tumor Meta-Analysis (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol 28:1247-1253, 2010
5. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008 (Pubitemid 351264358)
6. Blanke CD, Demetri GD, von Mehren M, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625, 2008 (Pubitemid 351264357)
7. DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58, 2000 (Pubitemid 30043939)
8. Rossi S, Miceli R, Messerini L, et al: Natural history of imatinib-naive GISTs: A retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 35:1646-1656, 2011
9. Joensuu H, Eriksson M, Sundby Hall K, et al: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307:1265-1272, 2012
10. Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1,765 cases with long-term follow-up. Am J Surg Pathol 29:52-68, 2005 (Pubitemid 40023952)
11. Miettinen M, Makhlouf H, Sobin LH, et al: Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477-489, 2006 (Pubitemid 43740149)
12. Gold JS, Gönen M, Gutiérrez A, et al: Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. Lancet Oncol 10:1045-1052, 2009
13. Joensuu H, Vehtari A, Riihimäki J, et al: Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. Lancet Oncol 13:265-274, 2012
14. Miettinen M, Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83, 2006 (Pubitemid 44692418)
15. Edge SB, Byrd DR, Compton CC, et al (eds): American Joint Commission on Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
16. Andersson J, Bumming P, Meis-Kindblom JM, et al: Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130:1573-1581, 2006 (Pubitemid 43668833)
17. Dematteo RP, Gold JS, Saran L, et al: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608-615, 2008 (Pubitemid 351186201)
18. Wardelmann E, Losen I, Hans V, et al: Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106:887-895, 2003 (Pubitemid 37071667)
19. Martin-Broto J, Gutierrez A, Garcia-del-Muro X, et al: Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 21:1552-1557, 2010
20. Wozniak A, Rutkowski P, Piskorz A, et al: Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 23:353-360, 2012
21. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009
22. Demetri GD, Heinrich MC, Fletcher JA, et al: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 15:5902-5909, 2009
23. Emile JF, Brahimi S, Coindre JM, et al: Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 29:1765-1772, 2012
24. Yantiss RK, Rosenberg AE, Sarran L, et al: Multiple gastrointestinal stromal tumors in type I neurofibromatosis: A pathologic and molecular study. Mod Pathol 18:475-484, 2005 (Pubitemid 40478110)
25. Kinoshita K, Hirota S, Isozaki K, et al: Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202:80-85, 2004 (Pubitemid 38072848)
26. Agaram NP, Wong GC, Guo T, et al: Novel V600E BRAF mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853-859, 2008
27. Miranda C, Nucifora M, Molinari F, et al: KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769-1776, 2012
28. Janeway KA, Kim SY, Lodish M, et al: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 108:314-318, 2011
29. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al: Succinate dehydrogenase-deficient GISTs: A clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 35:1712-1721, 2011
30. Wagner AJ, Remillard SP, Zhang YX, et al: Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 26:289-294, 2013
31. Italiano A, Chen CL, Sung YS, et al: SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer 12:408, 2012
32. Belinsky MG, Rink L, Flieder DB, et al: Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 52:214-224, 2013
33. Daniels M, Lurkin I, Pauli R, et al: Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 312:43-54, 2011
34. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003 (Pubitemid 46621810)
35. Cassier PA, Fumagalli E, Rutkowski P, et al: Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 18:4458-4464, 2012